EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Aberrant p53 immunostaining patterns in breast carcinoma of no special type strongly correlate with presence and type of TP53 mutations

Hannes Armbruster, Tilman Schotte, Isabell Götting, Mathis Overkamp, Massimo Granai, Lea Louise Volmer, Veronika Bahlinger, Sabine Matovina, André Koch, Dominik Dannehl, Tobias Engler, Andreas D Hartkopf und 5 weitere

Virchows Archiv · 2024

DOI: 10.1007/s00428-024-03897-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Virchows Archiv, 2024. Verfasst von Hannes Armbruster und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology and Neuropathology and Comprehensive Cancer Center Tübingen, Eberhard-Karls-University, Liebermeisterstraße 8, 72076, Tübingen…. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Breast Neoplasms, Mutation, Immunohistochemistry. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Eberhard Karls Universität Tübingen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent studies have revealed an association between TP53 mutations and endocrine resistance in hormone receptor-positive, HER2-negative breast cancer (HR + HER2 −BC). Aberrant p53 immunostaining (IHC) patterns may provide a surrogate marker for TP53 mutations. Building upon a ternary algorithm of aberrant staining patterns, this study evaluates the reliability of p53 IHC as screening tool for TP53 mutations in BC (NST). Furthermore, it describes the histopathological and molecular characteristics of TP53 -mutated cases, along with the mutational status of PIK3CA . This study comprised 131 early-stage, node-negative BCs with available core biopsies and resection specimens. Cases were categorized as follows: HR + HER2 − (85 cases), HER2 + (21 cases) and triple negative (TN, 25 cases). Aberrant IHC staining patterns for p53 were defined as overexpression (OE), complete absence (CA) and cytoplasmic (CY). In addition, targeted sequencing of TP53 and PIK3CA genes was performed. TP53 mutations were identified in 53 of 126 cases (42.1%). Within HR + HER2 − cases, TP53 mutations were found in 17 of 80 cases (21.3%). IHC accurately predicted TP53 mutation in 96.2% of cases with a specificity of 100%. Additionally, there was a significant agreement between missense mutations and OE, as well as between truncating mutations and CA (κ 73% and 76%). CY was observed in two TN cases with truncating mutations within the nuclear localization signalling domain of p53. TP53 -mutated cases exhibited higher grade, greater nuclear pleomorphism and higher Ki-67 proliferation index and were associated with the PIK3CA wild-type status ( p < 0.001). p53 IHC may provide a useful screening tool for identifying TP53 -mutated BC of NST.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor Suppressor Protein p53Breast NeoplasmsMutationImmunohistochemistryBiomarkers, TumorClass I Phosphatidylinositol 3-KinasesHumansFemaleMiddle AgedAdultAgedDNA Mutational AnalysisAged, 80 and overErb-b2 Receptor Tyrosine Kinases

Stichwörter der Autor:innen

PIK3CATP53 mutationBreast cancerImmunohistochemistryNGSP53

Substanzen

Tumor Suppressor Protein p53Biomarkers, TumorClass I Phosphatidylinositol 3-KinasesErb-b2 Receptor Tyrosine KinasesTP53 protein, humanPIK3CA protein, human

Autor:innen und Institutionen

  • Institute of Pathology and Neuropathology and Comprehensive Cancer Center Tübingen, Eberhard-Karls-University, Liebermeisterstraße 8, 72076, Tübingen, Germany.
  • Department of Woman's Health, Eberhard-Karls-University, Tübingen, Germany.
  • Institute of Pathology and Neuropathology and Comprehensive Cancer Center Tübingen, Eberhard-Karls-University, Liebermeisterstraße 8, 72076, Tübingen, Germany. Annette.Staebler@med.uni-tuebingen.de.

Förderung

  • Deutsche Forschungsgemeinschaft
  • Eberhard Karls Universität Tübingen

Zitieren

APA

Armbruster, H., Schotte, T., Götting, I., Overkamp, M., Granai, M., Volmer, L. L., Bahlinger, V., Matovina, S., Koch, A., Dannehl, D., Engler, T., Hartkopf, A. D., Brucker, S. Y., Bonzheim, I., Fend, F., Staebler, A., & Montes-Mojarro, I. (2024). Aberrant p53 immunostaining patterns in breast carcinoma of no special type strongly correlate with presence and type of TP53 mutations. Virchows Archiv. https://doi.org/10.1007/s00428-024-03897-3

Vancouver

Armbruster H, Schotte T, Götting I, Overkamp M, Granai M, Volmer LL, et al. Aberrant p53 immunostaining patterns in breast carcinoma of no special type strongly correlate with presence and type of TP53 mutations. Virchows Archiv. 2024. doi:10.1007/s00428-024-03897-3

BibTeX
@article{Armbruster2024,
  author = {Armbruster, Hannes and Schotte, Tilman and Götting, Isabell and Overkamp, Mathis and Granai, Massimo and Volmer, Lea Louise and Bahlinger, Veronika and Matovina, Sabine and Koch, André and Dannehl, Dominik and Engler, Tobias and Hartkopf, Andreas D and Brucker, Sara Y and Bonzheim, Irina and Fend, Falko and Staebler, Annette and Montes-Mojarro, Ivonne},
  title = {Aberrant p53 immunostaining patterns in breast carcinoma of no special type strongly correlate with presence and type of TP53 mutations},
  journal = {Virchows Archiv},
  year = {2024},
  doi = {10.1007/s00428-024-03897-3}
}
Kostenlos starten →